Bailard, Inc. Xencor Inc Transaction History

Bailard, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$33.67 - $43.44 $227,036 - $292,915	-6,743 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$30.65 - $35.68 $591,545 - $688,624	-19,300 Reduced 74.11%	6,743 $220,000
Q2 2021 Aug 13, 2021	BUY	$34.33 - $44.68 $199,114 - $259,144	5,800 Added 28.65%	26,043 $898,000
Q1 2021 May 13, 2021	BUY	$40.81 - $53.88 $248,941 - $328,668	6,100 Added 43.13%	20,243 $872,000
Q4 2020 Feb 03, 2021	SELL	$36.63 - $47.63 $109,890 - $142,890	-3,000 Reduced 17.5%	14,143 $617,000
Q3 2020 Nov 10, 2020	BUY	$30.09 - $43.02 $75,225 - $107,550	2,500 Added 17.07%	17,143 $665,000
Q4 2019 Jan 31, 2020	BUY	$32.75 - $41.43 $119,308 - $150,929	3,643 Added 33.12%	14,643 $504,000
Q1 2019 Apr 24, 2019	SELL	$27.85 - $38.09 $139,250 - $190,450	-5,000 Reduced 31.25%	11,000 $342,000
Q2 2018 Aug 08, 2018	SELL	$28.41 - $42.41 $105,117 - $156,917	-3,700 Reduced 18.78%	16,000 $592,000
Q1 2018 May 07, 2018	BUY	$21.18 - $33.78 $127,080 - $202,680	6,000 Added 43.8%	19,700 $591,000
Q4 2017 Feb 08, 2018	BUY	$19.29 - $24.83 $42,438 - $54,625	2,200 Added 19.13%	13,700 $0
Q4 2015 Jan 29, 2018	BUY	N/A	11,500	11,500 $0

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.23B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.